Navigation Links
U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
Date:1/12/2009

PITTSBURGH, Jan. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Dey L.P. has been issued several additional U.S. patents protecting the company's Perforomist(R) Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment.

U.S. Patent No. 7,462,645 was issued Dec. 9, 2008, and is directed to treatment through the administration of a ready-to-use, storage stable composition of formoterol. This patent covers Dey's Perforomist(R) Solution, and its term extends until June 22, 2021. The patent will be listed in the "Orange Book," giving Dey four Orange Book-listed patents covering Perforomist Solution.

U.S. Patent Nos. 7,465,756 and 7,473,710 were issued Dec. 16, 2008, and Jan. 6, 2009, respectively. These patents are directed to compositions of "R-formoterol," a specific form of the formoterol molecule, and their use.

In addition, Dey has received a "Notice of Allowance" on yet another patent also directed to the use of R-formoterol. This patent is expected to issue shortly. Upon its issuance, Dey will possess seven patents directed to compositions of formoterol, R-formoterol and/or their uses.

Mylan's Vice Chairman and CEO Robert J. Coury stated: "We are very pleased with the recent issuance of these additional patents, which we believe only further bolster Dey's already strong intellectual property portfolio, and we will continue to aggressively protect and assert Dey's IP rights. Dey is currently pursuing a patent infringement lawsuit against Sepracor relating to its Brovana(R) product."

Dey also has additional pending U.S. patent applications directed to formoterol-containing compositions and their use in the treatment of respiratory conditions.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey L.P. puts patients first through its development of innovative and affordable therapies. The Web sites for Dey L.P. include www.dey.com, www.accuneb.com, www.curosurfusa.com, www.cyanokit.com, www.duoneb.com, www.epipen.com and www.perforomist.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
2. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
3. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
4. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
5. Procter & Gamble Reaches Settlement on Patent Infringement Lawsuit
6. SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
7. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
8. FreePatentsOnline Launches the CitePatents Program : Making it Easy for Bloggers and Journalists to Reference Patents, and Add Patent Search to Websites
9. HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
10. Kidnapped senior needed IU-patented home security system
11. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... On Dec. ... the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have ... (MPNs) by going above and beyond the standard of care, demonstrating leadership within the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
Breaking Medicine Technology: